Sabina Mędrek
Kasper Rolek2
Sebastian Szmit- 1Department of Cardio-Oncology, Centre of Postgraduate Medical Education, Warsaw, Poland
- 2Department of Cardiology and Cardio-Oncology Unit, Subcarpathian Oncological Center, Brzozow, Poland
- 3Cardio-Oncology Unit, Maria Skłodowska-Curie National Research Institute of Oncology, Warsaw, Poland
Radiotherapy is an integral part of early breast cancer treatment, when breast-conserving surgery is performed. Heart disease caused by radiotherapy can include pericardial lesions, cardiac dysfunction, valvular defects, coronary artery damage, and cardiac arrhythmias. Risk factors primarily include those related to the mean heart dose of radiation, but with the development of modern radiotherapy techniques, this problem is optimistically decreasing. However, concurrent pharmacological anticancer therapies still significantly impact the vessels and heart. The key problem, however, is pre-existing heart disease, often based on atherosclerosis or arterial hypertension. Efforts should be made to ensure that radiotherapy produces at most permissive cardiotoxicity, which will not affect the quality of life or survival. Hence, effective pharmacotherapy for primary and secondary cardioprotection is searching.
1 Introduction
Breast cancer (BC) is the most common female malignancy worldwide (Siegel et al., 2024). According to the latest data from the National Cancer Registry (NCR), 21,554 new cases were recorded in 2022 in Poland, accounting for 23.6% of all malignancies diagnosed in women (Strona, 2025). Carcinoma of the male breast is rare, accounting for less than 1% of all cancer cases in men; in Poland, it corresponds to an annual estimate of about 140 cases (Strona, 2025; Fox et al., 2022). BC is also the second leading cause of cancer-related death among women, following lung cancer (LC). In 2022, 6,611 deaths were recorded in Poland, representing 14.9% of all cancer-related deaths among women (Strona, 2025). The aetiology of BC remains largely unclear. The most significant risk factors include female sex, advanced age, a positive family history of BC, and the presence of pathogenic gene variants, BRCA1 and BRCA2 mutations, as well as early menarche and late menopause. Modifiable risk factors include postmenopausal overweight and obesity, prolonged use of hormone replacement therapy, and long-term hormonal contraception (Brody et al., 2007). Individual cancer risk can be estimated using validated predictive models (Stark et al., 2019). The Gail model is the most widely used breast cancer risk assessment tool (Stevanato et al., 2022). This scale incorporates several clinical and demographic parameters, including current age, age at menarche, age at first live birth, first-degree family history of BC, number of previous breast biopsies, and atypical hyperplasia in biopsy. Approximately half of all cases occur in women with no identifiable risk factors other than female gender and age over 40 years (Who, 2025). This highlights the extremely complex interplay between environmental, lifestyle and genetic factors, as well as underscores the need for further research into the mechanisms underlying this disease.
1.1 Radiation therapy
Radiation therapy (RT) remains an essential component of BC management. It is most used in conjunction with systemic treatment and surgical intervention in cases of early-stage disease, as well as in the management of local recurrences. RT plays a pivotal role in adjuvant therapy following breast-conserving surgery. This combined treatment is no less effective than mastectomy and is currently the preferred treatment option (Veronesi et al., 2002; Moran et al., 2014). Postoperative RT reduces the risk of local recurrence and improves survival (Early Breast Cancer Trialists' Collaborative Group EBCTCG et al., 2011). Most commonly, beams with energies of 4–6 meV are used at a dose of 40 Gy in 15 fractions over 3 weeks (Smith et al., 2011) or at 26 Gy in 5 fractions over 1 week (Murray Brunt et al., 2020). Additionally, higher targeted doses may be administered to the tumour bed using photon beams, electron beams, or brachytherapy to reduce the risk of local recurrence (Bartelink et al., 2015).
1.2 Cardiovascular mortality among BC patients
Improvements in early diagnosis and advances in BC treatment have contributed to a reduction in the risk of cancer-related death in these patients (Sung et al., 2021). Therefore, it can be concluded that an increasing number of BC patients will die from conditions other than breast cancer. Cardiovascular disease (CVD) is the most common cause of death globally (Roth et al., 2020). A large cohort study has shown that for women aged ≥66 years who survived at least 5 years after breast cancer diagnosis, CVD became the leading cause of death by the 10-year mark, when the cumulative incidence of each was 5% (A et al., 2017). Another large cohort study found that CVD (15.9% (95% CI 15.6–16.2)), followed by BC (15.1% (95% CI 14.8–15.4)) was the leading cause of mortality across the entire study population of BC patients (Patnaik et al., 2011). Analysis of SEER data including 655,552 breast cancer cases has shown that the risk of CVD was significantly higher in BC patients compared to the general population and occurred mainly within 10 years of BC diagnosis (Luo et al., 2025). Multivariate analysis showed that RT was associated with an increased risk of CV death (RR ≈ 1.29 [95% CI: 1.13–1.48]) compared to women who did not receive such treatment (Cheng et al., 2017). Additionally, left-sided RT was associated with a significantly increased risk of cardiac death compared with right-sided treatment (RR 1.22, 95% CI 1.08–1.37, p = 0.002) (Cheng et al., 2017).
2 Radiation-induced heart disease
Thoracic radiotherapy, while significantly improving cancer survival, can cause radiation-induced heart disease (RIHD). The term encompasses pericardial disease, cancer treatment-related heart dysfunction (CTRCD), coronary artery disease, valvular heart disease, and conduction abnormalities (Ellahham et al., 2022). Furthermore, RIHD is exacerbated by systemic therapy and CV risk factors, including diabetes mellitus (DM), hypertension (HT), obesity, and dyslipidaemia. The estimated incidence of RIHD at 5–10 years post-treatment was 10%–30% and varied depending on RT duration and the type of cancer (Wang et al., 2019). The incidence of specific heart diseases in BC patients ranges from 0.5% to 37% (Wang et al., 2019).
Radiation-induced heart disease (RIHD) is a multifactorial process driven by a complex interplay of vascular, inflammatory, oxidative, and fibrotic mechanisms (Wang et al., 2019; Taunk et al., 2015). A central initiating event is endothelial injury, which occurs shortly after radiation exposure and leads to microvascular dysfunction, increased vascular permeability, pro-thrombotic changes, and chronic inflammation (Taunk et al., 2015; Madan et al., 2015). Ionizing radiation induces excessive production of reactive oxygen species (ROS), resulting in persistent oxidative stress, mitochondrial dysfunction, lipid peroxidation, and DNA damage in cardiomyocytes and vascular cells (Ping et al., 2020; Wang et al., 2020). These processes activate multiple pro-inflammatory and pro-fibrotic signaling pathways, including NF-KB and TGF-β/Smad, promoting fibroblast activation and excessive extracellular matrix deposition (Wang et al., 2020). Progressive myocardial fibrosis, together with apoptosis of cardiomyocytes and remodeling of coronary micro- and macrovessels, ultimately leads to diastolic and systolic dysfunction, ischemic heart disease, and heart failure (Šteiner, 2020). Importantly, these pathological processes may evolve silently over years or decades following radiotherapy, explaining the delayed clinical presentation of RIHD in long-term cancer survivors (Wang et al., 2019).
2.1 Pericardial diseases
Pericardial diseases are one of the most common and earliest manifestations of RIHD (Cuomo et al., 2016). RT can give rise to pericardial involvement by generating reactive oxygen species (ROS), which cause oxidative damage to pericardial cells, leading to increased membrane permeability, neutrophilic infiltration, and subsequent effusion (Pedersen et al., 2023). Cancer patients are diagnosed with pericardial conditions such as pericardial effusion, acute pericarditis, and constrictive pericarditis. Pericardial effusion, defined as the accumulation of fluid within the pericardial cavity, may result from direct tumour invasion or as a complication of anticancer therapies, including RT, chemotherapy (ChT), and immunotherapy (IT). It is one of the most common incidental findings in cancer patients, particularly in those with BC, and its presence has been linked with increased mortality (Chahine et al., 2021). Acute pericarditis may develop secondary to direct neoplastic infiltration or as a result of cancer treatments, IT or RT in particular. Management typically includes nonsteroidal anti-inflammatory drugs (NSAIDs), colchicine, and, in selected cases, corticosteroids or anti–interleukin-1 (IL-1) agents. In refractory or recurrent cases, pericardiocentesis, prolonged pericardial drainage, or pericardial window may be necessary. Constrictive pericarditis, although rare, most often develops as a late complication of RT. Its diagnosis is challenging and requires multimodal imaging, whereas surgical pericardiectomy remains the definitive treatment option.
2.2 Cardiac dysfunction
Historically, various terms and definitions have been used to describe the spectrum of cardiovascular toxicities associated with cancer therapy, leading to inconsistencies in diagnostic criteria and clinical management. The 2022 ESC Cardio-Oncology Guidelines established a unified definition of cancer therapy–related cardiac dysfunction (CTRCD), encompassing a wide range of clinical manifestations and an aetiological relationship with a wide range of cancer treatments, including ChT, targeted therapy, IT, and RT. CTRCD has been further classified as symptomatic and asymptomatic. Symptomatic CTRCD corresponds to clinically overt heart failure (HF), a syndrome defined by the presence of major symptoms such as dyspnoea and peripheral oedema, often accompanied by additional signs including elevated jugular venous pressure and pulmonary crackles. The asymptomatic form of CTRCD is typically classified based on left ventricular ejection fraction (LVEF): LVEF ≤40% (HF with reduced ejection fraction, HFrEF); LVEF 41%–49% (HF with mildly reduced ejection fraction, HFmrEF); and LVEF ≥50% (HF with preserved ejection fraction, HFpEF); a new relative reduction in global longitudinal strain (GLS) > 15% compared with baseline, ccTnI/cTnT>99 percentile, BNP ≥35 pg/mL, NT-proBNP ≥125 pg/mL, or new significant rise from baseline beyond the biological and analytical variation of the assay used (Lyon et al., 2022). Cardiac troponins and natriuretic peptides represent key biomarkers in the early detection and monitoring of CTRCD; their use enables prompt intervention before irreversible damage occurs (Tamburrini et al., 2025). Emerging biomarkers, such as microRNAs and soluble ST2, have shown potential as indicators of the risk of myocardial dysfunction in patients undergoing anticancer therapy. They hold promise for better risk prediction, but currently available evidence is insufficient for their routine use (Madan et al., 2015). The estimated prevalence of radiation-induced cardiomyopathy is >10%, with an increased incidence of HF compared to the general population (Belzile-Dugas and Eisenberg, 2021; Koutroumpakis et al., 2020). In a population-based case-control study published in 2017 involving women who developed HF following RT for breast cancer, 64% of cases presented with HFpEF (LVEF >50%), and 89% had an LVEF >40%, indicating a predominance of preserved or mildly reduced systolic function in this population (Saiki et al., 2017). This is likely due to damage to rapidly proliferating endothelial cells and inflammation during RT, which leads to impaired microcirculation, oxidative stress, myocarditis, and ultimately fibrosis. Cardiac dysfunction and progression of HF may also arise from coronary endotheliitis caused by comorbidities (Paulus and Tschöpe, 2013; Mohammed et al., 2015). Cardiomyocytes are nonproliferating cells, therefore they are resistant to radiation. Their damage secondary to infarction or other factors is the main mechanism of HFrEF (Bloom et al., 2016). Clinical symptoms of RT-induced cardiac fibrosis appear late, after approximately 10 years (Belzile-Dugas and Eisenberg, 2021; Finch et al., 2014). It therefore seems important to use other diagnostic modalities to allow for earlier detection of myocardial damage and possible implementation of cardioprotective treatment. The ESC Cardio-Oncology Guidelines further incorporate the assessment of the left ventricular global longitudinal strain and cardiac biomarkers in the definition of CTRCD. A reduction in ejection fraction and GLS was observed in left-sided BC patients with no prior history of cardiac treatment 6 months after RT (Ellahham et al., 2022). An attempt was also made to develop a predictive model for radiotherapy-induced cardiotoxicity, incorporating dosimetric, demographic, imaging, and clinical parameters (Talebi et al., 2025). The link between RT and changes in biomarker levels remains unclear; therefore, no specific recommendations have been offered for the prevention of radiation-induced heart damage (Pudil et al., 2020). In different studies, multivariate QRS analysis showed no association between mean heart dose [median (IQR): 2.87 Gy (2.05–3.94)] and post-RT biomarker levels (hsCRP, NT-proBNP, hsTnI) in left-sided BC patients treated with modern RT techniques (FIELD-W-FIELD IMRT/VMAT ± Deep Inspiration Breath Hold [DIBH]) (Chufal et al., 2024). In BC survivors with advanced HF refractory to pharmacotherapy, heart transplantation may be considered after a cancer remission period of 2–5 years (López-Fernández et al., 2024). Despite the higher incidence of secondary malignancies and infections in this population, survival rates are comparable to those of patients undergoing heart transplantation for other cardiomyopathies (López-Fernández et al., 2024).
2.3 Coronary artery disease
Advances in modern radiation therapy planning and the adoption of novel techniques can substantially reduce cardiac radiation exposure; however, even low cardiac exposure during breast cancer RT increase the risk of coronary events (Darby et al., 2013). The incidence of coronary artery disease (CAD) increases proportionally with the mean heart radiation dose. It has its onset a few years after exposure, and persists for at least 20 years (Darby et al., 2013), affecting up to 85% of patients (Chang et al., 2017a). Women with preexisting cardiac risk factors are at a greater absolute risk from RT than other women (Darby et al., 2013). Radiation-induced vascular injury is believed to promote atherosclerosis, particularly at high radiation doses (Chang et al., 2017b) and in experimental models (Wu et al., 2023). On the other hand, low and moderate doses may attenuate the inflammatory response and, consequently, reduce atherosclerotic plaque formation. Cardiac radiation at 5 Gy has been shown to exert beneficial effects on cardiac remodelling in both mice and in humans with HF (Pedersen et al., 2023). A Swedish cohort treated for BC between 1970 and 2003 showed a direct link between radiation dose and the location of coronary artery stenosis, the proximal right coronary artery (prox RCA), the mid and distal left anterior descending artery, and the distal diagonal branch (mdLAD + dD) in particular (Nilsson et al., 2012). Similar findings have been reported in other clinical trials (Wennstig et al., 2019; Jacob et al., 2019; Piroth et al., 2019). Patients with CV risk factors and a mean cardiac dose >5 Gy are at increased risk of cardiotoxicity and should be referred for Cardio-Oncology assessment. Coronary artery calcium (CAC) scores obtained from CT prior to planned radiotherapy may represent a valuable screening tool, warranting further investigation (Otero-Pla et al., 2025). The outcomes of percutaneous coronary intervention (PCI) for CAD may be comparable between patients with and without prior RT (Mitchell et al., 2021). Performing coronary artery bypass graft (CABG) may be challenging due to potential subclavian artery stenosis or LIMA atresia, which can limit the availability of this procedure (Zhang et al., 2019). In cases involving a heavily calcified (‘porcelain’) aorta, PCI is often the preferred treatment option (Zhang et al., 2019).
2.4 Valvular heart disease (VHD)
Radiation-induced VHD (RIVHD) is observed in nearly 81% of patients treated with thoracic RT (Zafar et al., 2020). The incidence and severity of VHD depend on multiple factors, primarily the radiation dose received. These patients have a 9.2-fold increased risk of requiring valvular surgery compared to non-irradiated individuals (Belzile-Dugas and Eisenberg, 2021). The overall incidence in BC patients ranges from 0.5% to 4.2% (Otero-Pla et al., 2025). The primary mechanism underlying valvular damage involves fibroblast activation and the release of fibroblast growth factor, resulting in fibrosis with or without calcification (Gujral et al., 2016). This can cause thickening and/or calcification of the valves, annulus, and supra- or subvalvular structures, giving rise to valvular stenosis and/or regurgitation. Left-sided valves are most commonly affected, regardless of dose distribution, suggesting that higher systemic pressure further contributes to valvular damage. Aortic regurgitation is the most common defect, followed by aortic stenosis. Since the aortic valve is typically closest to the radiation field, it is most frequently affected by both regurgitation and stenosis. Mitral and tricuspid valve abnormalities have also been reported. As opposed to rheumatic heart disease, mitral valve commissures and leaflet tips are typically spared with radiation (Hering et al., 2003). As the disease progresses, patients may require interventional or surgical valve replacement. The standardised incidence rate ratio for valve surgery compared with a healthy age and sex-matched population was 9.2 (95% confidence interval 8.1–10.3) (Gujral et al., 2016). However, the rates of mortality and adverse events were higher after both interventional and surgical valve replacement in RIVHD patients vs. controls (Belzile-Dugas and Eisenberg, 2021). Patients with prior thoracic RT and severe aortic stenosis have poorer outcomes after any type of valve replacement than those without a history of RT. Retrospective cohorts of these patients (Zhang et al., 2019; Donnellan et al., 2017) seem to have better outcomes after TAVR vs. surgical aortic valve replacement (SAVR), although a subgroup of patients at low surgical risk may potentially be successfully treated with SAVR. SAVR may be considered in patients at lower surgical risk (e.g., younger age), especially those with technical/anatomical challenges associated with TAVR or those who require additional surgical interventions such as pericardiectomy, multiple valve surgery, or CABG (Zhang et al., 2019).
2.5 Arrhythmias
The incidence of cardiac arrhythmias in patients undergoing RT ranges from 2% to 19% (Bedi et al., 2023). There are diverse, largely dose-dependent mechanisms leading to different types of cardiac arrhythmias. However, the observed relationship between the mean heart dose (MHD) and coronary complications cannot be directly extrapolated to arrhythmia. Few studies have assessed the risk of arrhythmia in relation to the mean cardiac exposure, cardiac substructure doses in particular. A study in LC patients treated with RT found that arrhythmic events showed significant borderline correlations between the mean whole heart dose and the right atrium dose, but not with the left ventricular or left atrial dose (Wang et al., 2017). Other studies demonstrated that the radiation dose to the right atrium may be a more significant parameter than the mean whole-heart dose in evaluating the risk of arrhythmia, and that right-sided irradiation is associated with greater exposure of the right atrium compared to other cardiac structures (Errahmani et al., 2022). Both the sinoatrial node (SAN) and the atrioventricular node (AVN) may be substantially exposed during breast VMAT, particularly in right-sided cases (Loap et al., 2023). Studies evaluating nodal exposure may help establish dose constraints and criteria for additional cardiac-sparing techniques, such as respiratory techniques or proton therapy, which could bring benefit in patients with underlying rhythmic or conduction disorders (Loap et al., 2023). It was also observed that, despite the moderate dose range received by the SAN and AVN in BC patients treated with 3D-CRT, SAN was the most exposed cardiac structure in right-sided BC. This finding may explain previous results indicating a higher risk of arrhythmia and conduction disturbances in right-sided vs. left-sided BC, as well as a potential association with the right atrial dose (Errah et al., 2022). A large registry-based cohort study involving 8,015 BC patients diagnosed between 2001 and 2008 in the Stockholm-Gotland region, and followed until 2017, demonstrated an increased long-term risk of arrhythmia and heart failure following BC diagnosis. The hazard ratios (HRs) within the first year post-diagnosis were 2.14 (95% CI: 1.63–2.81) for arrhythmia and 2.71 (95% CI: 1.70–4.33) for HF. After more than 10 years post-diagnosis, the HRs were 1.42 (95% CI: 1.21–1.67) for arrhythmia and 1.28 (95% CI: 1.03–1.59) for HF (Yang et al., 2022). Other studies have suggested that patients with axillary lymph node involvement have a threefold higher risk of cardiotoxicity due to more intensive systemic therapy and increased radiation exposure to sensitive coronary structures (Guo et al., 2025).
Atrial fibrillation (AF), which typically occurs within 2 months after RT completion, is the most common arrhythmia observed in BC patients (Wang et al., 2019). In terms of pathophysiology, AF is conventionally defined as arrhythmia arising from arrhythmogenic ectopic foci located in damaged myocardial tissue within the pulmonary veins (PV) (Lau et al., 2017; Haïssaguerre et al., 1998). Based on these mechanisms, it is likely that radiation-induced PV fibrosis (O'Sullivan and Levin, 2003) contributes to AF as a late sequel of RT (Walls et al., 2024). The maximum dose to PVs (PVd max) appears to be a significant predictor of AF, independent of other risk factors and even after dose adjustment to adjacent cardiac substructures associated with AF (Butler et al., 2024). The incidence of AF is generally higher in BC patients and is largely related to the stage of disease at diagnosis (Guha et al., 2022). Additionally, a cohort study of 560 LC patients demonstrated that the maximum dose delivered to the sinoatrial node was an independent factor associated with atrial fibrillation and overall survival (Kim et al., 2022). RT also causes autonomic dysfunction, most likely secondary to reduced vagal tone. This results in the loss of circadian heart rate variability, persistent tachycardia, and an inappropriate chronotropic response to stress and exercise. Abnormal post-exercise heart rate recovery (HRR) time was observed in 32% of RT patients vs. 9% controls (Groarke et al., 2015). Increased all-cause mortality was also reported over a median follow-up of 3 years in patients with abnormal post-exercise HRR time (Groarke et al., 2015).
Although RT-induced conduction abnormalities are rare, affecting approximately 4%–5% of patients overall, up to 75% of patients receiving mediastinal RT present with ECG abnormalities (Belzile-Dugas and Eisenberg, 2021; Koutroumpakis et al., 2020; Chang et al., 2017b). The conduction system may be directly damaged by radiation in an inflammatory process leading to fibrosis or as a result of fibrosis following myocardial ischaemia (Orzan et al., 1993). RT has been associated with a higher incidence of QT prolongation, ventricular tachycardia, atrioventricular block, fascicular block, and bundle branch block, most commonly right bundle branch block as the right bundle is located anteriorly and lies directly within the radiation field (Chang et al., 2017b; Larsen et al., 1992). A French study involving 3,853 BC patients showed that RT-treated patients had a higher risk of requiring permanent pacemaker implantation (PPMI) compared with the general population, with 28 observed cases versus 13 expected, corresponding to a standardised incidence ratio (SIR) of 2.18 (95% CI: 1.45–3.06]) (Errahmani et al., 2021).
RT can also lead to implantable cardiac device dysfunction (ICSD), which may be either transient or may result in permanent device damage (Zaremba et al., 2016). The recommended safe energy is 6 MV, with dose limits ≤2 Gy for pacemakers and 1 Gy for implantable cardioverter-defibrillators (ICDs) (Sabater et al., 2018). These devices should be regularly monitored both during and after RT, particularly in those who are pacemaker-dependent.
The diagnosis and treatment of radiation-induced arrhythmia require the same diagnostic tools and therapeutic interventions as arrhythmias of other aetiologies, including electrocardiography (ECG), Holter monitoring, antiarrhythmic drugs, and implantation of a pacemaker or ICD.
3 Risk factors for RIHD
Multiple factors contribute to RIHD, including prior and ongoing anticancer treatments, as well as modifiable (lifestyle-related) and non-modifiable (sociodemographic characteristics and pre-existing heart disease) patient-related risk factors. It is crucial to identify and modify these factors to reduce the risk of cardiovascular events associated with anticancer therapy while simultaneously preventing premature treatment discontinuation.
3.1 RT-associated risk factors
Primary prevention of radiation-induced cardiovascular damage depends on the use of advanced techniques to minimize cardiac exposure. However, it is not always possible to completely avoid cardiac exposure due to the proximity of the heart to the tumour (e.g., during lymph node irradiation in BC). Such approaches can preserve or even enhance RT efficacy while reducing the risk of cancer therapy–related cardiovascular toxicity (CTR-CVT) (Lyon et al., 2022). A key objective of modern RT techniques is to minimize MHD, which is recommended as a more reliable parameter for assessing the risk of RT-induced cardiovascular toxicity, as the administered radiation dose may not accurately represent the actual cardiac exposure (Darby et al., 2013; Maraldo et al., 2015). The BACCARAT study showed that MHD alone is insufficient to accurately predict the individual patient’s dose to LV and coronary arteries, the left anterior descending artery (LAD) in particular. It is therefore necessary to consider dose distribution within these specific cardiac substructures rather than MHD alone for precise assessment of RT-induced cardiotoxicity (Wennstig et al., 2019). For this reason, there are ongoing discussions about the safest radiation dose as well as the most appropriate strategies to minimize the risk of RT-induced CVD (Jacob et al., 2019; Hoppe et al., 2020). The heart is considered a vulnerable organ during RT and its radiation exposure should be as low as possible, as there is no “safe” dose (Darby et al., 2013; van Nimwegen et al., 2016). Strategies to prevent and limit CV complications of RT include modifications of cancer treatment to avoid RT (Fuchs et al., 2019; Radford et al., 2015; Kunkler et al., 2015), as well as modifications of the dose and volume of the RT area, if possible. Modern heart-sparing RT techniques include intensity-modulated photon radiotherapy (IMPT), deep inspiratory breath-hold (DIBH), and respiratory-gated techniques for the treatment of BC (Song et al., 2020), as well as imaging-guided radiotherapy and proton beam irradiation (Dabaja et al., 2018). A population-based study by the Danish Breast Cancer Group showed that patients undergoing CT-guided RT did not have an increased risk of cardiac events in left-sided BC patients compared to right-sided BC patients during the first 10 years post-RT, in contrast to the non-CT-guided RT, where a significantly higher risk of cardiac events was observed in left-sided BC patients (Milo et al., 2021). DIBH is one of the most effective heart-sparing techniques in breast cancer RT. Care should be taken to identify patients who do not benefit from this labour-intensive procedure or who benefit less than an alternative approach: if whole-breast irradiation WBI is necessary - prone positioning, or if lymph node RT is necessary, IMRT may be alternative options (Gaál et al., 2021).
3.2 Systemic cancer therapy-related risk factors
Systemic therapy combined with surgery is used both pre- and postoperatively, and both strategies show similar efficacy in primarily resectable tumours (Mauri et al., 2005; Early Breast Cancer Trialists’ Collaborative Group EBCTCG, 2018). However, in recent years, there has been a tendency to use preoperative (neoadjuvant) systemic therapy, as it allows for limiting the scope of surgery in the breast and axilla, and for assessing the individual response to the applied systemic treatment modality (Jassem et al., 2020). Depending on the histopathological diagnosis, systemic treatment includes chemotherapy, hormonal therapy, and/or molecularly targeted therapies. Anthracyclines (doxorubicin and epirubicin), cyclophosphamide, taxanes (doctaxel and paclitaxel), anti-HER2 (trastuzumab, pertuzumab), carboplatin, methotrexate, and tamoxifen are most commonly used. All of these have documented cardiotoxic effects of varying intensity and extent (Bird and Swain, 2008; Schmitz et al., 2012; Cardinale et al., 2015). Although rastuzumab and other HER2-targeted monoclonal antibodies are effective in treating HER2-positive breast cancer, they can cause cardiotoxicity, HF in particular (Copeland-Halperin et al., 2019). Trastuzumab combined with anthracyclines increases the risk of cardiac damage. Studies have shown that 8.7% of trastuzumab-treated patients experience significant decreases in LVEF, which can lead to HF (Jerusalem et al., 2019; Slamon et al., 2011). The addition of pertuzumab to trastuzumab improves cancer outcomes, but may also increase cardiac risk (von Minckwitz et al., 2017). Antibody-drug conjugates such as trastuzumab-emtansine (T-DM1) or trastuzumab-deruxtecan (T-DXd) demonstrate reduced cardiotoxicity compared to trastuzumab alone (Colombo and Rich, 2022).
3.3 Patient-related risk factors
Classic cardiovascular risk factors, including hypertension (HT), diabetes mellitus (DM), hyperlipidaemia, a family history of coronary artery disease (CAD), and pre-existing CVD, are associated with an increased risk of RIHD (Lyon et al., 2022; Belzile-Dugas and Eisenberg, 2021). This association was supported by a study in Korean BC patients, which demonstrated that the risk of acute coronary syndromes and cardiac mortality was lower among women without these risk factors (Chang J. S. et al., 2017). This analysis also demonstrated that obesity (a modifiable risk factor) was an independent predictor of cardiac mortality, with 5% increase in the risk of cardiac death for each 1 kg/m2 increase in body mass index (BMI) (Chang J. S. et al., 2017). Furthermore, smoking during RT was associated with a threefold higher risk of myocardial infarction (MI) (Hooning et al., 2007). Cardiovascular risk following adjuvant RT has been shown to increase with decreasing levels of physical activity (Chang et al., 2019). Therefore, a baseline CV risk assessment, including blood pressure, lipid profile, fasting glucose, HbA1c, and electrocardiography (ECG), is recommended, along with patient education on maintaining a healthy lifestyle and managing lifestyle-related risk factors (Lyon et al., 2022). Additionally, a 10-year risk of fatal and non-fatal CVD events should be estimated using SCORE2 (age <70 years) or SCORE2-OP (age ≥70 years): age <50 years: low risk <2.5%, moderate risk 2.5% to <7.5%, high risk ≥7.5%; age 50–69 years: low risk <5%; moderate risk 5% to <10%; high risk ≥10%; age ≥70 years: low risk <7.5%, moderate risk 7.5% to <15%, high risk ≥15% (Visseren et al., 2021).
4 General principles of RIHD prevention
Based on the most recent cardiological (ESC 2022) and oncological (ESMO, ASTRO) guidelines, the following preventive measures have been proposed (Figure 1) (Lyon et al., 2022; Shaitelman et al., 2024; Curigliano et al., 2020; Plana et al., 2014).
Figure 1. Possibilities of RIHD prevention.
4.1 Risk assessment before starting RT
CV history and assessment of risk factors (HT, DM, dyslipidaemia, smoking, heart disease), ECG and echocardiography in high-risk patients, biomarker testing (troponin, BNP) – optional.
4.2 Optimization of RT
The use of heart-sparing techniques: IMRT, VMAT, proton therapy, DIBH, avoidance of exceeding dose limits: average dose to the heart <5 Gy, minimization of exposure to the left ventricle and coronary arteries.
4.3 Modification of CV risk factors
Treatment of HT, DM, and hypercholesterolaemia; smoking cessation; promoting a healthy diet and physical activity.
4.4 Pharmacological prophylaxis
Statins in patients with increased cardiac risk; ACE inhibitors or ARBs in patients with HT or left ventricular dysfunction; and beta-blockers in patients with IHD or a history of MI.
4.5 Cardiac monitoring after RT
Regular assessment of blood pressure, lipid levels, and glycaemia; echocardiography 6–12 months after completion of RT (in high-risk patients), and then every 2–5 years; biomarkers—to be considered in symptomatic or high-risk patients.
4.6 Interdisciplinary care
Collaboration among the oncologist, radiotherapist, and cardiologist, with cardiology consultation in cases of abnormalities or coexisting heart disease.
5 Pharmacological prevention of RIHD
There are no proven conservative treatments for preventing RT-induced CV toxicity (Lyon et al., 2022). Although some medications, including statins, ACE inhibitors, and B-blockers, have been reported to contribute to RIHD prevention (Zhang et al., 2015; Huang et al., 2024; O et al., 2009; van der Veen et al., 2015), these are experimental studies. β-blockers, ACE inhibitors, and sodium-glucose cotransporter 2 inhibitors may help improve cardiac dysfunction associated with anticancer therapy, but clinical trials are inconsistent, and therefore individually tailored treatment is needed (Tamburrini et al., 2025).
5.1 Statins
Studies in animal and cellular models have shown that statins can reduce oxidative stress, inflammation, and radiation-induced mitochondrial damage by activating adenosine monophosphate-activated protein kinase (AMPK) (Sun et al., 2006). Zhang et al. demonstrated in an experimental rat model that atorvastatin is effective for radiation-induced cardiac fibrosis, particularly with higher doses and longer use (Zhang et al., 2015). A retrospective cohort study in Taiwan involving 1,481 left-sided BC patients who underwent breast-conserving surgery and adjuvant RT demonstrated that statins significantly reduced the risk of major adverse cardiovascular events (MACEs). The 5-year cumulative incidence of MACEs was 12.24% in patients receiving statins, compared with 31.70% of nonusers. The greatest cardioprotective effect was shown for hydrophobic statins, such as rosuvastatin and pravastatin (Huang et al., 2024). These findings suggest a potential role for statins in reducing CV complications in this population and highlight the need for further research to optimize statin therapy. Another meta-analysis demonstrated that statin use was associated with reduced BC mortality for lipophilic statins and decreased all-cause mortality for both lipophilic and hydrophilic statins (Chang et al., 2023; Liu et al., 2017). A meta-analysis of observational studies showed that post-diagnosis statin use was associated with reduced BC mortality, while pre-diagnosis statin use was negatively correlated with both all-cause and cancer-specific mortality (Zhong et al., 2015). On the other hand, a retrospective analysis of 748 patients with locally advanced non-small cell lung cancer (NSCLC) undergoing chest RT found that statin use was inversely associated with survival rates (Atkins et al., 2021). A possible explanation is that patients in the statin group had a higher prevalence of CV risk factors. Therefore, prospective studies are needed to investigate the role of statins in radiation-induced cardiotoxicity and to provide a comprehensive assessment of baseline cardiac risk and cardiac radiation exposure (Jiang et al., 2024). Further research is therefore needed to determine the optimal timing of statin therapy in the context of RT, to identify which patient groups benefit most from such intervention, and to assess the long-term effects of statin use in this population. Currently, the inclusion of statins in the treatment regimen of patients undergoing RT should be considered on an individual basis, taking into account the patient’s overall cardiovascular risk profile.
5.2 ACE inhibitors
ACEIs act by inhibiting the renin-angiotensin-aldosterone system (RAAS), leading to a decrease in the production of reactive oxygen species (ROS), reducing oxidative stress and inflammation, increasing the production of nitric oxide (NO), protecting endothelial cells (Dong et al., 2020), and reducing perivascular fibrosis and apoptosis of myocardial cells after cardiac exposure to radiation (Wang et al., 2020). Van der Veen et al. (van der Veen et al., 2015) demonstrated a protective effect of captopril. It improves cardiopulmonary morphology and function by reducing acute cardiac injury. Although preclinical data suggest potential benefits of ACEIs in preventing RIHD, clinical trials confirming their efficacy in this patient population are currently lacking. Therefore, routine use of ACEIs for preventing RIHD in BC patients undergoing RT cannot yet be clearly recommended.
5.3 Beta-blockers
Beta-blockers block β1 (and/or β2) adrenergic receptors in the heart, reducing heart rate, which limits myocardial oxygen consumption. They also limit the activation of proinflammatory cytokines, reducing the risk of fibrosis and cardiac dysfunction. They improve endothelial function and coronary blood flow. Some of them (e.g., carvedilol) have antioxidant effects, neutralizing ROS, which protects cardiomyocytes from apoptosis and fibrosis. A retrospective cohort study showed that metoprolol is associated with a reduced risk of CV mortality in BC patients (Tabassum et al., 2024). Another meta-analysis suggested that beta-blockers were associated with longer RFS in patients with early-stage BC, with a more pronounced effect observed in patients with triple-negative breast cancer (TNBC) (Caparica et al., 2021). β-blocker use has also been shown to significantly reduce the risk of death from breast cancer (Childers et al., 2015). However, further research is needed to confirm these findings and understand their mechanism of action.
6 Emerging therapeutic strategies with adaptive potential: mesenchymal stem cell–based approaches
In addition to conventional pharmacological cardioprotection, mesenchymal stem cell (MSC)–based therapies have emerged as a promising experimental strategy for mitigating radiation-induced cardiac injury (Wang et al., 2021; Wang et al., 2025). Preclinical studies demonstrate that transplantation of bone marrow-derived MSCs significantly attenuates myocardial damage after cardiac irradiation by enhancing DNA repair pathways, reducing oxidative stress, and improving microvascular integrity (Gao et al., 2017). The therapeutic benefits of MSCs are largely mediated through paracrine mechanisms, including the secretion of vascular endothelial growth factor (VEGF), insulin-like growth factor (IGF), stromal-derived factor-1 (SDF-1), and anti-inflammatory cytokines (Gao et al., 2017; Windmolders et al., 2014). More recently, MSC-derived extracellular vesicles (MSC-EVs) have gained considerable attention as cell-free therapeutic agents capable of modulating apoptosis, inflammation, mitochondrial dysfunction, calcium homeostasis, and fibrotic signaling in irradiated cardiac tissue and cardiac organoid models (Cao et al., 2024; Luo et al., 2021). Despite these encouraging findings, current evidence for MSC-based therapy in RIHD remains limited to experimental and early translational studies (Wang et al., 2021; Wang et al., 2025). Significant challenges—including optimal cell sourcing, delivery strategies, long-term safety, oncologic safety, and reproducibility of therapeutic effects—must be addressed before clinical implementation (Wang et al., 2025; Maria et al., 2016). Nevertheless, MSC-based and MSC-EV–based approaches represent a promising future direction for adaptive and regenerative treatment of radiation-induced cardiac injury (Wang et al., 2021; Kong et al., 2025).
7 Conclusion
Advances in BC detection and treatment have led to the need for new research, including more cardioprotective radiotherapy techniques. Due to the complexity of factors influencing cardiovascular risk, both treatment-related and patient-specific risk factors should be considered in treatment planning. These risk factors should be modified at every stage of treatment. Cardiotoxicity significantly compromises the quality of life, even in patients with early-stage BC (Murg et al., 2024), further emphasising the need for early cardiac monitoring and interventions. Further research is needed to assess the impact of radiotherapy on mortality and cardiovascular risk, and to assess the possibility of pharmacological prevention. Raising cardio-oncological awareness and promoting interdisciplinary collaboration are essential to advancing patient care. Initiatives focused on education, improving access to cardio-oncology services, and formal training programmes are essential for addressing any existing shortcomings (Dauccia et al., 2025).
Author contributions
SM: Writing – original draft, Writing – review and editing. KR: Writing – original draft, Writing – review and editing. JH: Writing – review and editing, Writing – original draft. SS: Writing – review and editing, Writing – original draft.
Funding
The author(s) declared that financial support was received for this work and/or its publication. Funding: The study supported by the Centre of Postgraduate Medical Education. Program No 501-1-142-21-25.
Conflict of interest
The author(s) declared that this work was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Generative AI statement
The author(s) declared that generative AI was not used in the creation of this manuscript.
Any alternative text (alt text) provided alongside figures in this article has been generated by Frontiers with the support of artificial intelligence and reasonable efforts have been made to ensure accuracy, including review by the authors wherever possible. If you identify any issues, please contact us.
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
References
Abdel-Qadir, H., Austin, P. C., Lee, D. S., Amir, E., Tu, J. V., Thavendiranathan, P., et al. (2017). A population-based study of cardiovascular mortality following early-stage breast cancer. JAMA Cardiol. 2 (1), 88–93. doi:10.1001/jamacardio.2016.3841
Atkins, K. M., Bitterman, D. S., Chaunzwa, T. L., Williams, C. L., Rahman, R., Kozono, D. E., et al. (2021). Statin use, heart radiation dose, and survival in locally advanced lung cancer. Pr. Oncol. 11 (5), e459–e467. doi:10.1016/j.prro.2020.12.006
Bartelink, H., Maingon, P., Poortmans, P., Weltens, C., Fourquet, A., Jager, J., et al. (2015). Whole-breast irradiation with or without a boost for patients treated with breast-conserving surgery for early breast cancer: 20-year follow-up of a randomised phase 3 trial. Lancet Oncol. 16 (1), 47–56. doi:10.1016/S1470-2045(14)71156-8
Bedi, R., Ahmad, A., Horbal, P., and Mar, P. L. (2023). Radiation-associated arrhythmias: putative pathophysiological mechanisms, prevalence, screening and management strategies. ArrhythmElectrophysiol Rev. 12, e24. doi:10.15420/aer.2022.44
Belzile-Dugas, E., and Eisenberg, M. J. (2021). Radiation-induced cardiovascular disease: review of an underrecognized pathology. J. Am. Heart Assoc. 10 (18), e021686. doi:10.1161/JAHA.121.021686
Bird, B. R., and Swain, S. M. (2008). Cardiac toxicity in breast cancer survivors: review of potential cardiac problems. Clin. Cancer Res. 14 (1), 14–24. doi:10.1158/1078-0432.CCR-07-1033
Bloom, M. W., Hamo, C. E., Cardinale, D., Ky, B., Nohria, A., Baer, L., et al. (2016). Cancer therapy-related cardiac dysfunction and heart failure: part 1: definitions, pathophysiology, risk factors, and imaging. Circ. Heart Fail 9 (1), e002661. doi:10.1161/CIRCHEARTFAILURE.115.002661
Brody, J. G., Rudel, R. A., Michels, K. B., Moysich, K. B., Bernstein, L., Attfield, K. R., et al. (2007). Environmental pollutants, diet, physical activity, body size, and breast cancer: where do we stand in research to identify opportunities for prevention? Cancer 109 (12 Suppl. l), 2627–2634. doi:10.1002/cncr.22656
Butler, S., No, H., Guo, F., Merchant, G., Park, N. J., Jackson, S., et al. (2024). Predictors of atrial fibrillation after thoracic radiotherapy. JACC CardioOncol 6 (6), 935–945. doi:10.1016/j.jaccao.2024.08.007
Cao, H., Yue, L., Shao, J., Kong, F., Liu, S., Huai, H., et al. (2024). Small extracellular vesicles derived from umbilical cord mesenchymal stem cells alleviate radiation-induced cardiac organoid injury. Stem Cell Res. Ther. 15 (1), 493. doi:10.1186/s13287-024-04115-2
Caparica, R., Bruzzone, M., Agostinetto, E., De Angelis, C., Fêde, Â., Ceppi, M., et al. (2021). Beta-blockers in early-stage breast cancer: a systematic review and meta-analysis. ESMO Open 6 (2), 100066. doi:10.1016/j.esmoop.2021.100066
Cardinale, D., Colombo, A., Bacchiani, G., Tedeschi, I., Meroni, C. A., Veglia, F., et al. (2015). Early detection of anthracycline cardiotoxicity and improvement with heart failure therapy. Circulation 131 (22), 1981–1988. doi:10.1161/CIRCULATIONAHA.114.013777
Chahine, J., Shekhar, S., Mahalwar, G., Imazio, M., Collier, P., and Klein, A. (2021). Pericardial involvement in cancer. Am. J. Cardiol. 145, 151–159. doi:10.1016/j.amjcard.2020.12.092
Chang, H. M., Okwuosa, T. M., Scarabelli, T., Moudgil, R., and Yeh, E. T. H. (2017a). Cardiovascular complications of cancer therapy: best practices in diagnosis, prevention, and management: part 2. J. Am. Coll. Cardiol. 70 (20), 2552–2565. doi:10.1016/j.jacc.2017.09.1095
Chang, H. M., Moudgil, R., Scarabelli, T., Okwuosa, T. M., and Yeh, E. T. H. (2017b). Cardiovascular complications of cancer therapy: best practices in diagnosis, prevention, and management: part 1. J. Am. Coll. Cardiol. 70 (20), 2536–2551. doi:10.1016/j.jacc.2017.09.1096
Chang, J. S., Ko, B. K., Bae, J. W., Yu, J. H., Park, M. H., Jung, Y., et al. (2017). Korean breast cancer society. Radiation-related heart disease after breast cancer radiation therapy in Korean women. Breast Cancer Res. Treat. 166 (1), 249–257. doi:10.1007/s10549-017-4398-y
Chang, J. S., Shin, J., Park, E. C., and Kim, Y. B. (2019). Risk of cardiac disease after adjuvant radiation therapy among breast cancer survivors. Breast 43, 48–54. doi:10.1016/j.breast.2018.11.003
Chang, W. T., Lin, H. W., Lin, S. H., and Li, Y. H. (2023). Association of statin use with Cancer- and noncancer-associated survival among patients with breast cancer in Asia. JAMA Netw. Open 6 (4), e239515. doi:10.1001/jamanetworkopen.2023.9515
Cheng, Y. J., Nie, X. Y., Ji, C. C., Lin, X. X., Liu, L. J., Chen, X. M., et al. (2017). Long-term cardiovascular risk after radiotherapy in women with breast cancer. J. Am. Heart Assoc. 6 (5), e005633. doi:10.1161/JAHA.117.005633
Childers, W. K., Hollenbeak, C. S., and Cheriyath, P. (2015). β-Blockers reduce breast cancer recurrence and breast cancer death: a meta-analysis. Clin. Breast Cancer 15 (6), 426–431. doi:10.1016/j.clbc.2015.07.001
Chufal, K., Ahmad, I., Prakash, A., Miller, A., Umesh, P., Koul, V., et al. (2024). Cardiac markers in left-sided breast cancer patients receiving adjuvant radiotherapy: a prospective study. Cardiooncology 10 (1), 21. doi:10.1186/s40959-024-00225-1
Colombo, R., and Rich, J. R. (2022). The therapeutic window of antibody drug conjugates: a dogma in need of revision. Cancer Cell 40 (11), 1255–1263. doi:10.1016/j.ccell.2022.09.016
Copeland-Halperin, R. S., Liu, J. E., and Yu, A. F. (2019). Cardiotoxicity of HER2-targeted therapies. Curr. Opin. Cardiol. 34 (4), 451–458. doi:10.1097/HCO.0000000000000637
Cuomo, J. R., Sharma, G. K., Conger, P. D., and Weintraub, N. L. (2016). Novel concepts in radiation-induced cardiovascular disease. World J. Cardiol. 8 (9), 504–519. doi:10.4330/wjc.v8.i9.504
Curigliano, G., Lenihan, D., Fradley, M., Ganatra, S., Barac, A., Blaes, A., et al. (2020). ESMO guidelines committee. Electronic address:Y2xpbmljYWxndWlkZWxpbmVzQGVzbW8ub3Jn. Management of cardiac disease in cancer patients throughout oncological treatment: ESMO consensus recommendations. Ann. Oncol. 31 (2), 171–190. doi:10.1016/j.annonc.2019.10.023
Dabaja, B. S., Hoppe, B. S., Plastaras, J. P., Newhauser, W., Rosolova, K., Flampouri, S., et al. (2018). Proton therapy for adults with mediastinal lymphomas: the international lymphoma radiation oncology group guidelines. Blood 132 (16), 1635–1646. doi:10.1182/blood-2018-03-837633
Darby, S. C., Ewertz, M., McGale, P., Bennet, A. M., Blom-Goldman, U., Brønnum, D., et al. (2013). Risk of ischemic heart disease in women after radiotherapy for breast cancer. N. Engl. J. Med. 368 (11), 987–998. doi:10.1056/NEJMoa1209825
Dauccia, C., Agostinetto, E., Arecco, L., Lobo-Martins, S., Gitto, M., Lyon, A. R., et al. (2025). Cardiovascular toxicity of breast cancer treatments: from understanding to enhancing survivorship care. ESMO Open 10 (6), 105128. doi:10.1016/j.esmoop.2025.105128
Dong, H., Yao, L., Wang, M., Wang, M., Li, X., Sun, X., et al. (2020). Can ACEI/ARB prevent the cardiotoxicity caused by chemotherapy in early-stage breast cancer? a meta-analysis of randomized controlled trials. Transl. Cancer Res. 9 (11), 7034–7043. doi:10.21037/tcr-20-1869
Donnellan, E., Masri, A., Johnston, D. R., Pettersson, G. B., Rodriguez, L. L., Popovic, Z. B., et al. (2017). Long-term outcomes of patients with mediastinal radiation-associated severe aortic stenosis and subsequent surgical aortic valve replacement: a matched cohort study. J. Am. Heart Assoc. 6 (5), e005396. doi:10.1161/JAHA.116.005396
Early Breast Cancer Trialists' Collaborative Group (EBCTCG) (2018). Long-term outcomes for neoadjuvant versus adjuvant chemotherapy in early breast cancer: meta-analysis of individual patient data from ten randomised trials. Lancet Oncol. 19 (1), 27–39. doi:10.1016/S1470-2045(17)30777-5
Early Breast Cancer Trialists' Collaborative Group (EBCTCG) Darby, S., McGale, P., Correa, C., Taylor, C., Arriagada, R., et al. (2011). Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death: meta-analysis of individual patient data for 10,801 women in 17 randomised trials. Lancet 378 (9804), 1707–1716. doi:10.1016/S0140-6736(11)61629-2
Ellahham, S., Khalouf, A., Elkhazendar, M., Dababo, N., and Manla, Y. (2022). An overview of radiation-induced heart disease. Radiat. Oncol. J. 40 (2), 89–102. doi:10.3857/roj.2021.00766
Errahmani, M. Y., Locquet, M., Broggio, D., Spoor, D., Jimenez, G., Camilleri, J., et al. (2022). Supraventricular cardiac conduction system exposure in breast cancer patients treated with radiotherapy and association with heart and cardiac chambers doses. Clin. TranslRadiat Oncol. 38, 62–70. doi:10.1016/j.ctro.2022.10.015
Errahmani, M. Y., Thariat, J., Ferrières, J., Panh, L., Locquet, M., Lapeyre-Mestre, M., et al. (2021). Risk of pacemaker implantation after radiotherapy for breast cancer: a study based on French nationwide health care database sample. Int. J. Cardiol. Heart Vasc. 38, 100936. doi:10.1016/j.ijcha.2021.100936
Errahmani, M. Y., Locquet, M., Spoor, D., Jimenez, G., Camilleri, J., Bernier, M. O., et al. (2022). Association between cardiac radiation exposure and the risk of arrhythmia in breast cancer patients treated with radiotherapy: a case-control study. Front. Oncol. 12, 892882. doi:10.3389/fonc.2022.892882
Finch, W., Shamsa, K., and Lee, M. S. (2014). Cardiovascular complications of radiation exposure. Rev. Cardiovasc Med. 15 (3), 232–244. doi:10.3909/ricm0689
Fox, S., Speirs, V., and Shaaban, A. M. (2022). Male breast cancer: an update. Virchows Arch. 480 (1), 85–93. doi:10.1007/s00428-021-03190-7
Fuchs, M., Goergen, H., Kobe, C., Kuhnert, G., Lohri, A., Greil, R., et al. (2019). Positron emission tomography-guided treatment in early-stage favorable hodgkin lymphoma: final results of the international, randomized phase III HD16 trial by the German Hodgkin study group. J. Clin. Oncol. 37 (31), 2835–2845. doi:10.1200/JCO.19.00964
Gaál, S., Kahán, Z., Paczona, V., Kószó, R., Drencsényi, R., Szabó, J., et al. (2021). Deep-inspirational breath-hold (DIBH) technique in left-sided breast cancer: various aspects of clinical utility. Radiat. Oncol. 16 (1), 89. doi:10.1186/s13014-021-01816-3
Gao, S., Zhao, Z., Wu, R., Zeng, Y., Zhang, Z., Miao, J., et al. (2017). Bone marrow mesenchymal stem cell transplantation improves radiation-induced heart injury through DNA damage repair in rat model. Radiat. Environ. Biophys. 56 (1), 63–77. doi:10.1007/s00411-016-0675-0
Groarke, J. D., Tanguturi, V. K., Hainer, J., Klein, J., Moslehi, J. J., Ng, A., et al. (2015). Abnormal exercise response in long-term survivors of hodgkin lymphoma treated with thoracic irradiation: evidence of cardiac autonomic dysfunction and impact on outcomes. J. Am. Coll. Cardiol. 65 (6), 573–583. doi:10.1016/j.jacc.2014.11.035
Guha, A., Fradley, M. G., Dent, S. F., Weintraub, N. L., Lustberg, M. B., Alonso, A., et al. (2022). Incidence, risk factors, and mortality of atrial fibrillation in breast cancer: a SEER-medicare analysis. Eur. Heart J. 43 (4), 300–312. doi:10.1093/eurheartj/ehab745
Gujral, D. M., Lloyd, G., and Bhattacharyya, S. (2016). Radiation-induced valvular heart disease. Heart 102 (4), 269–276. doi:10.1136/heartjnl-2015-308765
Guo, F. B., No, H. J., Park, N. J., Butler, S., Jackson, S., Rhee, J. W., et al. (2025). Risk factors of cardiotoxicity after breast cancer radiotherapy. Adv. Radiat. Oncol. 10 (12), 101911. doi:10.1016/j.adro.2025.101911
Haïssaguerre, M., Jaïs, P., Shah, D. C., Takahashi, A., Hocini, M., Quiniou, G., et al. (1998). Spontaneous initiation of atrial fibrillation by ectopic beats originating in the pulmonary veins. N. Engl. J. Med. 339 (10), 659–666. doi:10.1056/NEJM199809033391003
Hering, D., Faber, L., and Horstkotte, D. (2003). Echocardiographic features of radiation-associated valvular disease. Am. J. Cardiol. 92 (2), 226–230. doi:10.1016/s0002-9149(03)00546-0
Hooning, M. J., Botma, A., Aleman, B. M. P., Baaijens, M. H. A., Bartelink, H., Klijn, J. G. M., et al. (2007). Long-term risk of cardiovascular disease in 10-Year survivors of breast cancer. JNCI J. Natl. Cancer Inst. 99 (5), 365–375. doi:10.1093/jnci/djk064
Hoppe, B. S., Bates, J. E., Mendenhall, N. P., Morris, C. G., Louis, D., Ho, M. W., et al. (2020). The meaningless meaning of mean heart dose in mediastinal lymphoma in the modern radiation therapy era. Pr. Oncol. 10 (3), e147–e154. doi:10.1016/j.prro.2019.09.015
Huang, Y. J., Lin, J. A., Chen, W. M., Shia, B. C., and Wu, S. Y. (2024). Statin therapy reduces radiation-induced cardiotoxicity in patients with breast cancer receiving adjuvant radiotherapy. J. Am. Heart Assoc. 13 (20), e036411. doi:10.1161/JAHA.124.036411
Jacob, S., Camilleri, J., Derreumaux, S., Walker, V., Lairez, O., Lapeyre, M., et al. (2019). Is mean heart dose a relevant surrogate parameter of left ventricle and coronary arteries exposure during breast cancer radiotherapy: a dosimetric evaluation based on individually-determined radiation dose (BACCARAT study). Radiat. Oncol. 14 (1), 29. doi:10.1186/s13014-019-1234-z
Jassem, J., Krzakowski, M., Bobek-Billewicz, B., Duchnowska, R., Jeziorski, A., Olszewski, W., et al. (2020). Onkologia w Praktyce Klinicznej – Edukacja, 297–352. Available online at: https://journals.viamedica.pl/onkologia_w_praktyce_klin_edu/article/view/71321.
Jerusalem, G., Lancellotti, P., and Kim, S. B. (2019). HER2+ breast cancer treatment and cardiotoxicity: monitoring and management. Breast Cancer Res. Treat. 177 (2), 237–250. doi:10.1007/s10549-019-05303-y
Jiang, R., Lou, L., Shi, W., Chen, Y., Fu, Z., Liu, S., et al. (2024). Statins in mitigating anticancer treatment-related cardiovascular disease. Int. J. Mol. Sci. 25 (18), 10177. doi:10.3390/ijms251810177
Kim, K. H., Oh, J., Yang, G., Lee, J., Kim, J., Gwak, S. Y., et al. (2022). Association of sinoatrial node radiation dose with atrial fibrillation and mortality in patients with lung cancer. JAMA Oncol. 8 (11), 1624–1634. doi:10.1001/jamaoncol.2022.4202
Kong, Y., Yang, C., Xie, L., Zhao, Y., Rong, Z., Zhou, X., et al. (2025). Cardiac toxicity and intervention strategies during thoracic cancer radiotherapy. Front. Oncol. 15, 1638035. doi:10.3389/fonc.2025.1638035
Koutroumpakis, E., Palaskas, N. L., Lin, S. H., Abe, J. I., Liao, Z., Banchs, J., et al. (2020). Modern radiotherapy and risk of cardiotoxicity. Chemotherapy 65 (3-4), 65–76. doi:10.1159/000510573
Kunkler, I. H., Williams, L. J., Jack, W. J. L., Cameron, D. A., and Dixon, J. M.PRIME II investigators (2015). Breast-conserving surgery withor without irradiation in women aged 65 years or older with earlybreast cancer (PRIME II): a randomised controlled trial. Lancet Oncol. 16 (3), 266–273. doi:10.1016/S1470-2045(14)71221-5
Larsen, R. L., Jakacki, R. I., Vetter, V. L., Meadows, A. T., Silber, J. H., and Barber, G. (1992). Electrocardiographic changes and arrhythmias after cancer therapy in children and young adults. Am. J. Cardiol. 70 (1), 73–77. doi:10.1016/0002-9149(92)91393-i
Lau, D. H., Linz, D., Schotten, U., Mahajan, R., Sanders, P., and Kalman, J. M. (2017). Pathophysiology of paroxysmal and persistent atrial fibrillation: rotors, foci and fibrosis. Heart Lung Circ. 26 (9), 887–893. doi:10.1016/j.hlc.2017.05.119
Liu, B., Yi, Z., Guan, X., Zeng, Y. X., and Ma, F. (2017). The relationship between statins and breast cancer prognosis varies by statin type and exposure time: a meta-analysis. Breast Cancer Res. Treat. 164 (1), 1–11. doi:10.1007/s10549-017-4246-0
Loap, P., Goudjil, F., Servois, V., Kirov, K., Fourquet, A., and Kirova, Y. (2023). Radiation exposure of cardiac conduction nodes during breast proton therapy. Int. J. Part Ther. 10 (1), 59–64. doi:10.14338/IJPT-22-00038.1
López-Fernández, T., Marco, I., Aznar, M. C., Barac, A., Bergler-Klein, J., Meattini, I., et al. (2024). Breast cancer and cardiovascular health. Eur. Heart J. 45 (41), 4366–4382. doi:10.1093/eurheartj/ehae637
Luo, L., Yan, C., Fuchi, N., Kodama, Y., Zhang, X., Shinji, G., et al. (2021). Mesenchymal stem cell-derived extracellular vesicles as probable triggers of radiation-induced heart disease. Stem Cell Res. Ther. 12 (1), 422. doi:10.1186/s13287-021-02504-5
Luo, Y., Zhao, L., Qu, P., Han, S., Wang, Y., Li, X., et al. (2025). The risk of heart-specific death in breast cancer patients. Sci. Rep. 15 (1), 28228. doi:10.1038/s41598-025-12648-6
Lyon, A. R., López-Fernández, T., Couch, L. S., Asteggiano, R., Aznar, M. C., Bergler-Klein, J., et al. (2022). 2022 ESC guidelines on cardio-oncology developed in collaboration with the european hematology association (EHA), the european society for therapeutic radiology and oncology (ESTRO) and the international cardio-oncology society (IC-OS). Eur. Heart J. 43 (41), 4229–4361. doi:10.1093/eurheartj/ehac244
Madan, R., Benson, R., Sharma, D. N., Julka, P. K., and Rath, G. K. (2015). Radiation induced heart disease: pathogenesis, management and review literature. J. Egypt Natl. Canc Inst. 27 (4), 187–193. doi:10.1016/j.jnci.2015.07.005
Maraldo, M. V., Giusti, F., Vogelius, I. R., Lundemann, M., van der Kaaij, M. A. E., Ramadan, S., et al. (2015). Cardiovascular disease aftertreatment for Hodgkin’s lymphoma: an analysis of nine collaborative EORTC-LYSA trials. Lancet Haematol. 2 (11), e492–e502. doi:10.1016/S2352-3026(15)00153-2
Maria, O. M., Shalaby, M., Syme, A., Eliopoulos, N., and Muanza, T. (2016). Adipose mesenchymal stromal cells minimize and repair radiation-induced oral mucositis. Cytotherapy 18 (9), 1129–1145. doi:10.1016/j.jcyt.2016.06.008
Mauri, D., Pavlidis, N., and Ioannidis, J. P. (2005). Neoadjuvant versus adjuvant systemic treatment in breast cancer: a meta-analysis. J. Natl. Cancer Inst. 97 (3), 188–194. doi:10.1093/jnci/dji021
Milo, M. L. H., Thorsen, L. B. J., Johnsen, S. P., Nielsen, K. M., Valentin, J. B., Alsner, J., et al. (2021). Risk of coronary artery disease after adjuvant radiotherapy in 29,662 early breast cancer patients: a population-based Danish breast cancer group study. Radiother. Oncol. 157, 106–113. doi:10.1016/j.radonc.2021.01.010
Mitchell, J. D., Cehic, D. A., Morgia, M., Bergom, C., Toohey, J., Guerrero, P. A., et al. (2021). Cardiovascular manifestations from therapeutic radiation: a multidisciplinary expert consensus statement from the international cardio-oncology society. JACC CardioOncol 3 (3), 360–380. doi:10.1016/j.jaccao.2021.06.003
Mohammed, S. F., Hussain, S., Mirzoyev, S. A., Edwards, W. D., Maleszewski, J. J., and Redfield, M. M. (2015). Coronary microvascular rarefaction and myocardial fibrosis in heart failure with preserved ejection fraction. Circulation 131 (6), 550–559. doi:10.1161/CIRCULATIONAHA.114.009625
Moran, M. S., Schnitt, S. J., Giuliano, A. E., Harris, J. R., Khan, S. A., Horton, J., et al. (2014). Society of surgical oncology-american society for radiation oncology consensus guideline on margins for breast-conserving surgery with whole-breast irradiation in stages I and II invasive breast cancer. J. Clin. Oncol. 32 (14), 1507–1515. doi:10.1200/JCO.2013.53.3935
Murg, S. I., Matiş, L., Moldovan, A. F., Schwarz-Madar, A. F., Trifan, D. F., Ghitea, T. C., et al. (2024). Cardiotoxicity in breast cancer: impact of clinical classifications and treatment on heart health. Cancers (Basel) 16 (24), 4281. doi:10.3390/cancers16244281
Murray Brunt, A., Haviland, J. S., Wheatley, D. A., Sydenham, M. A., Alhasso, A., Bloomfield, D. J., et al. (2020). Hypofractionated breast radiotherapy for 1 week versus 3 weeks (FAST-Forward): 5-year efficacy and late normal tissue effects results from a multicentre, non-inferiority, randomised, phase 3 trial. Lancet 395 (10237), 1613–1626. doi:10.1016/S0140-6736(20)30932-6
Nilsson, G., Holmberg, L., Garmo, H., Duvernoy, O., Sjögren, I., Lagerqvist, B., et al. (2012). Distribution of coronary artery stenosis after radiation for breast cancer. J. Clin. Oncol. 30 (4), 380–386. doi:10.1200/JCO.2011.34.5900
Ostrau, C., Hülsenbeck, J., Herzog, M., Schad, A., Torzewski, M., Lackner, K. J., et al. (2009). Lovastatin attenuates ionizing radiation-induced normal tissue damage in vivo. Radiother. Oncol. 92 (3), 492–499. doi:10.1016/j.radonc.2009.06.020
O'Sullivan, B., and Levin, W. (2003). Late radiation-related fibrosis: pathogenesis, manifestations, and current management. Semin. Radiat. Oncol. 13 (3), 274–289. doi:10.1016/S1053-4296(03)00037-7
Orzan, F., Brusca, A., Conte, M. R., Presbitero, P., and Figliomeni, M. C. (1993). Severe coronary artery disease after radiation therapy of the chest and mediastinum: clinical presentation and treatment. Br. Heart J. 69 (6), 496–500. doi:10.1136/hrt.69.6.496
Otero-Pla, E., Fuentes Raspall, M. J., Gallego Franco, P., Fernández Martínez, J., GichSaladich, I., Jornet Sala, N., et al. (2025). Mapping clinical and imaging factors that might predict cardiac events in breast cancer patients. Front. Oncol. 15, 1552908. doi:10.3389/fonc.2025.1552908
Patnaik, J. L., Byers, T., DiGuiseppi, C., Dabelea, D., and Denberg, T. D. (2011). Cardiovascular disease competes with breast cancer as the leading cause of death for older females diagnosed with breast cancer: a retrospective cohort study. Breast Cancer Res. 13 (3), R64. doi:10.1186/bcr2901
Paulus, W. J., and Tschöpe, C. (2013). A novel paradigm for heart failure with preserved ejection fraction: comorbidities drive myocardial dysfunction and remodeling through coronary microvascular endothelial inflammation. J. Am. Coll. Cardiol. 62 (4), 263–271. doi:10.1016/j.jacc.2013.02.092
Pedersen, L. N., Valenzuela Ripoll, C., Ozcan, M., Guo, Z., Lotfinaghsh, A., Zhang, S., et al. (2023). Cardiac radiation improves ventricular function in mice and humans with cardiomyopathy. Med 4 (12), 928–943.e5. doi:10.1016/j.medj.2023.10.006
Ping, Z., Peng, Y., Lang, H., Xinyong, C., Zhiyi, Z., Xiaocheng, W., et al. (2020). Oxidative stress in radiation-induced cardiotoxicity. Oxid. Med. Cell Longev. 2020, 3579143. doi:10.1155/2020/3579143
Piroth, M. D., Baumann, R., Budach, W., Dunst, J., Feyer, P., Fietkau, R., et al. (2019). Heart toxicity from breast cancer radiotherapy: current findings, assessment, and prevention. StrahlentherOnkol 195 (1), 1–12. doi:10.1007/s00066-018-1378-z
Plana, J. C., Galderisi, M., Barac, A., Ewer, M. S., Ky, B., Scherrer-Crosbie, M., et al. (2014). Expert consensus for multimodality imaging evaluation of adult patients during and after cancer therapy: a report from the American society of echocardiography and the European association of cardiovascular imaging. J. Am. Soc. Echocardiogr. 27 (9), 911–939. doi:10.1016/j.echo.2014.07.012
Pudil, R., Mueller, C., Čelutkienė, J., Henriksen, P. A., Lenihan, D., Dent, S., et al. (2020). Role of serum biomarkers in cancer patients receiving cardiotoxic cancer therapies: a position statement from the cardio-oncology study group of the heart failure association and the cardio-oncology council of the european Society of Cardiology. Eur. J. Heart Fail 22 (11), 1966–1983. doi:10.1002/ejhf.2017
Radford, J., Illidge, T., Counsell, N., Hancock, B., Pettengell, R., Johnson, P., et al. (2015). Results of a trial of PET-directed therapy for early-stage Hodgkin's lymphoma. N. Engl. J. Med. 372 (17), 1598–1607. doi:10.1056/NEJMoa1408648
Roth, G. A., Mensah, G. A., Johnson, C. O., Addolorato, G., Ammirati, E., Baddour, L. M., et al. (2020). Global burden of cardiovascular diseases and risk factors, 1990–2019: update from the GBD 2019 study. J. Am. Coll. Cardiol. 76 (25), 2982–3021. doi:10.1016/j.jacc.2020.11.010
Sabater, S., Montero, A., López Fernández, T., González Ferrer, J. J., and Arenas, M. (2018). Management of patients with implanted cardiac devices during radiotherapy: results of a Spanish survey in radiation oncology departments. Clin. Transl. Oncol. 20 (12), 1577–1581. doi:10.1007/s12094-018-1893-5
Saiki, H., Petersen, I. A., Scott, C. G., Bailey, K. R., Dunlay, S. M., Finley, R. R., et al. (2017). Risk of heart failure with preserved ejection fraction in older women after contemporary radiotherapy for breast cancer. Circulation 135 (15), 1388–1396. doi:10.1161/CIRCULATIONAHA.116.025434
Schmitz, K. H., Prosnitz, R. G., Schwartz, A. L., and Carver, J. R. (2012). Prospective surveillance and management of cardiac toxicity and health in breast cancer survivors. Cancer 118 (8 Suppl. l), 2270–2276. doi:10.1002/cncr.27462
Shaitelman, S. F., Anderson, B. M., Arthur, D. W., Bazan, J. G., Bellon, J. R., Bradfield, L., et al. (2024). Partial breast irradiation for patients with early-stage invasive breast cancer or ductal carcinoma in situ: an ASTRO clinical practice guideline. Pr. Oncol. 14 (2), 112–132. doi:10.1016/j.prro.2023.11.001
Siegel, R. L., Giaquinto, A. N., and Jemal, A. (2024). Cancer statistics, 2024. CA Cancer J. Clin. 74 (1), 12–49. doi:10.3322/caac.21820
Slamon, D., Eiermann, W., Robert, N., Pienkowski, T., Martin, M., Press, M., et al. (2011). Adjuvant trastuzumab in HER2-positive breast cancer. N. Engl. J. Med. 365 (14), 1273–1283. doi:10.1056/NEJMoa0910383
Smith, B. D., Bentzen, S. M., Correa, C. R., Hahn, C. A., Hardenbergh, P. H., Ibbott, G. S., et al. (2011). Fractionation for whole breast irradiation: an American society for radiation oncology (ASTRO) evidence-based guideline. Int. J. Radiat. Oncol. Biol. Phys. 81 (1), 59–68. doi:10.1016/j.ijrobp.2010.04.042
Song, A. J., Manukian, G., Taylor, A. K., Anne, P. R., and Simone, N. L. (2020). Concerns for active breathing control (ABC) with breast cancer in the era of COVID-19: maximizing infection control while minimizing heart dose. Adv. Radiat. Oncol. 5 (4), 573–574. doi:10.1016/j.adro.2020.03.009
Stark, G. F., Hart, G. R., Nartowt, B. J., and Deng, J. (2019). Predicting breast cancer risk using personal health data and machine learning models. PLoS One 14 (12), e0226765. doi:10.1371/journal.pone.0226765
Šteiner, I. (2020). Pathology of radiation induced heart disease. Rep. Pract. Oncol. Radiother. 25 (2), 178–181. doi:10.1016/j.rpor.2019.12.015
Stevanato, K. P., Pedroso, R. B., Dell Agnolo, C. M., Santos, L. D., Pelloso, F. C., Carvalho, M. D. B., et al. (2022). Use and applicability of the gail model to calculate breast cancer risk: a scoping review. Asian Pac J. Cancer Prev. 23 (4), 1117–1123. doi:10.31557/APJCP.2022.23.4.1117
Strona, G. (2025). Krajowy rejestrów pacjentów. Dostępne w internecie pod adresem. Available online at: https://onkologia.org.pl/pl.
Sun, W., Lee, T. S., Zhu, M., Gu, C., Wang, Y., Zhu, Y., et al. (2006). Statins activate AMP-activated protein kinase in vitro and in vivo. Circulation 114 (24), 2655–2662. doi:10.1161/CIRCULATIONAHA.106.630194
Sung, H., Ferlay, J., Siegel, R. L., Laversanne, M., Soerjomataram, I., Jemal, A., et al. (2021). Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 71 (3), 209–249. doi:10.3322/caac.21660
Tabassum, M., Chikermane, S. G., Johnson, C., Abdulkareem, N. M., Wang, E. M., Johnson, M. L., et al. (2024). Comparing the effects of various β-blockers on cardiovascular mortality in breast cancer patients. Cardiooncology 10 (1), 17. doi:10.1186/s40959-024-00217-1
Talebi, A., Bitarafan-Rajabi, A., Alizadeh-Asl, A., Seilani, P., Khajetash, B., Hajianfar, G., et al. (2025). Machine learning based radiomics model to predict radiotherapy induced cardiotoxicity in breast cancer. J. Appl. Clin. Med. Phys. 26 (4), e14614. doi:10.1002/acm2.14614
Tamburrini, G., de Cobos García, C., and López-Fernández, T. (2025). Advances in cardioprotection strategies: focusing on breast cancer and beyond through novel biomarkers and pharmacological approaches. Eur. Cardiol. 20, e23. doi:10.15420/ecr.2025.26
Taunk, N. K., Haffty, B. G., Kostis, J. B., and Goyal, S. (2015). Radiation-induced heart disease: pathologic abnormalities and putative mechanisms. Front. Oncol. 5, 39. doi:10.3389/fonc.2015.00039
van der Veen, S. J., Ghobadi, G., de Boer, R. A., Faber, H., Cannon, M. V., Nagle, P. W., et al. (2015). ACE inhibition attenuates radiation-induced cardiopulmonary damage. Radiother. Oncol. 114 (1), 96–103. doi:10.1016/j.radonc.2014.11.017
van Nimwegen, F. A., Schaapveld, M., Cutter, D. J., Janus, C. P., Krol, A. D., Hauptmann, M., et al. (2016). Radiation dose-response relationship for risk of coronary heart disease in survivors of Hodgkin Lymphoma. J. Clin. Oncol. 34 (3), 235–243. doi:10.1200/JCO.2015.63.4444
Veronesi, U., Cascinelli, N., Mariani, L., Greco, M., Saccozzi, R., Luini, A., et al. (2002). Twenty-year follow-up of a randomized study comparing breast-conserving surgery with radical mastectomy for early breast cancer. N. Engl. J. Med. 347 (16), 1227–1232. doi:10.1056/NEJMoa020989
Visseren, F. L. J., Mach, F., Smulders, Y. M., Carballo, D., Koskinas, K. C., Bäck, M., et al. (2021). ESC guidelines on cardiovascular disease prevention in clinical practice. Eur. Heart J. 42 (34), 3227–3337. doi:10.1093/eurheartj/ehab484
von Minckwitz, G., Procter, M., de Azambuja, E., Zardavas, D., Benyunes, M., Viale, G., et al. (2017). APHINITY steering committee and investigators. Adjuvant pertuzumab and trastuzumab in early HER2-Positive breast cancer. N. Engl. J. Med. 377 (2), 122–131. doi:10.1056/NEJMoa1703643
Wang, K., Pearlstein, K. A., Patchett, N. D., Deal, A. M., Mavroidis, P., Jensen, B. C., et al. (2017). HeartDosimetric analysis of three types of cardiac toxicity in PatientsTreated on dose-escalation trials for stage III non-small-cell lung cancer. Radiother. Oncol. 125 (2), 293–300. doi:10.1016/j.radonc.2017.10.001
Walls, G. M., McCann, C., O'Connor, J., O'Sullivan, A., I Johnston, D., McAleese, J., et al. (2024). Pulmonary vein dose and risk of atrial fibrillation in patients with non-small cell lung cancer following definitive radiotherapy: an NI-HEART analysis. Radiother. Oncol. 192, 110085. doi:10.1016/j.radonc.2024.110085
Wang, H., Wei, J., Zheng, Q., Meng, L., Xin, Y., Yin, X., et al. (2019). Radiation-induced heart disease: a review of classification, mechanism and prevention. Int. J. Biol. Sci. 15 (10), 2128–2138. doi:10.7150/ijbs.35460
Wang, B., Wang, H., Zhang, M., Ji, R., Wei, J., Xin, Y., et al. (2020). Radiation-induced myocardial fibrosis: mechanisms underlying its pathogenesis and therapeutic strategies. J. Cell Mol. Med. 24 (14), 7717–7729. doi:10.1111/jcmm.15479
Wang, K. X., Cui, W. W., Yang, X., Tao, A. B., Lan, T., Li, T. S., et al. (2021). Mesenchymal stem cells for mitigating radiotherapy side effects. Cells 10 (2), 294. doi:10.3390/cells10020294
Wang, N., Ma, F., Song, H., He, N., Zhang, H., Li, J., et al. (2025). Mesenchymal stem cell-derived extracellular vesicles for regenerative applications and radiotherapy. Cell Transpl. 34, 9636897241311019. doi:10.1177/09636897241311019
Wennstig, A. K., Garmo, H., Isacsson, U., Gagliardi, G., Rintelä, N., Lagerqvist, B., et al. (2019). The relationship between radiation doses to coronary arteries and location of coronary stenosis requiring intervention in breast cancer survivors. Radiat. Oncol. 14 (1), 40. doi:10.1186/s13014-019-1242-z
WHO (2025). Breast cancer. Available online at: https://www.who.int/news-room/fact-sheets/detail/breast-cancer. (Accessed October 5, 2025).
Windmolders, S., De Boeck, A., Koninckx, R., Daniëls, A., De Wever, O., Bracke, M., et al. (2014). Mesenchymal stem cell secreted platelet derived growth factor exerts a pro-migratory effect on resident cardiac atrial appendage stem cells. J. Mol. Cell Cardiol. 66, 177–188. doi:10.1016/j.yjmcc.2013.11.016
Wu, Z., Chen, T., Qian, Y., Luo, G., Liao, F., He, X., et al. (2023). High-dose ionizing radiation accelerates atherosclerotic plaque progression by regulating P38/NCOA4-Mediated Ferritinophagy/Ferroptosis of endothelial cells. Int. J. Radiat. Oncol. Biol. Phys. 117 (1), 223–236. doi:10.1016/j.ijrobp.2023.04.004
Yang, H., Bhoo-Pathy, N., Brand, J. S., Hedayati, E., Grassmann, F., Zeng, E., et al. (2022). Risk of heart disease following treatment for breast cancer - results from a population-based cohort study. Elife 11, e71562. doi:10.7554/eLife.71562
Zafar, M. R., Mustafa, S. F., Miller, T. W., Alkhawlani, T., and Sharma, U. C. (2020). Wyniki po przezcewnikowej wymianie zastawki aortalnej u osób, które przeżyły raka, z wcześniejszą radioterapią klatki piersiowej: przegląd systematyczny i metaanaliza. Kardionkologia. 2020 Lipiec 14, 6:8. doi:10.1186/s40959-020-00062-y
Zaremba, T., Jakobsen, A. R., Søgaard, M., Thøgersen, A. M., and Riahi, S. (2016). Radiotherapy in patients with pacemakers and implantable cardioverter defibrillators: a literature review. Europace 18 (4), 479–491. doi:10.1093/europace/euv135
Zhang, K., He, X., Zhou, Y., Gao, L., Qi, Z., Chen, J., et al. (2015). Atorvastatin ameliorates radiation-induced cardiac fibrosis in rats. Radiat. Res. 184 (6), 611–620. doi:10.1667/RR14075.1
Zhang, D., Guo, W., Al-Hijji, M. A., El Sabbagh, A., Lewis, B. R., Greason, K., et al. (2019). Outcomes of patients with severe symptomatic aortic valve stenosis after chest radiation: transcatheter versus surgical aortic valve replacement. J. Am. Heart Assoc. 8, e012110. doi:10.1161/JAHA.119.012110
Keywords: cardio-oncology, cardioprotection, coronary artery disease, heart disease, radiotherapy
Citation: Mędrek S, Rolek K, Homotnik J and Szmit S (2026) Cardioprotection for radiation-induced heart disease in breast cancer patients. Front. Pharmacol. 16:1742769. doi: 10.3389/fphar.2025.1742769
Received: 09 November 2025; Accepted: 11 December 2025;
Published: 06 January 2026.
Edited by:
Dieter Steinhilber, Goethe University Frankfurt, GermanyReviewed by:
Carlos Vera, Stanford University, United StatesXingjian Zhang, Nanchang University, China
Copyright © 2026 Mędrek, Rolek, Homotnik and Szmit. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Sebastian Szmit, cy5zem1pdEBnbWFpbC5jb20=